

be known only after the prices of concerned formulations have been fixed/revised as per provisions of DPCO, 1987, wherever necessary.

(b) to (d) DPCO, 1987 is based on the measures announced by the Government in December, 1986, details of which are contained in the booklet "Measures for Rationalisation, Quality Control and Growth of Drugs and Pharmaceutical Industry in India" copies of which are available in the Parliament Library.

**Exclusion from price control of Intestopan, etc.**

2352. SHRI RAFIQUE ALAM: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 237 given in the Rajya Sabha on the 9th November, 1987 and state:

(a) whether it is a fact that the main criteria for exclusion of drugs from price control as laid down by the Kelkar Committee were:

(i) turn-over of less than rupees fifty lakhs during 1986 and

(ii) that the production structure should be competitive and not in a monopoly position;

(b) if so, how the drugs have been excluded from price control without working out the turn-over of drugs during 1986;

(c) whether it is also a fact that Intestopan, Pancretine, Glipizide, Oxyfedrine Hcl., Isoxsuprine Hcl., Nondrolone Decanoate Nandrolons Phenyl Propionate have been recommended for price decontrol by the Kelkar Committee based on the set criteria;

(d) if so, on what specific criterion each drug was recommended for exclusion from price control; and

(e) what was the sales turnover of each during 1986?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI R. K. JAI-

CHANDRA SINGH): (a) to (e) The Kelkar Committee considered the recent WHO list of essential drugs and another 166 drugs listed in Annexure III of the Committee's report for possible inclusion in Category II list and adopted the following criteria for exclusion from Category II List:

(i) Exclude those drugs which are not produced in India, provided that the consumption is not significant either now or in the near future.

(ii) To exclude those drugs the turn over of which has been less than rupees fifty lakhs in 1986.

(iii) To exclude all new drugs for which process of manufacture were developed indigenously from the price control list at least for the First 5 years.

(iv) To exclude those life-saving drugs and pharmaceutical products whose availability is far more important than the price. As the nature of demand is such that it is required less frequently but its non-availability is fatal. The notable examples of such categories are sera and vaccines.

(v) Exclude those pharmaceutical products of drugs where the domestic production structure is so competitive that there is little possibility that the consumers will be over-charged compared to the cost of production.

On the basis of the above criteria the Committee recommended drugs to be included in Category II.

**Time Schedule for meter reading by DESU**

2353. SHRI JAGADISH JANI: Will the Minister of ENERGY be pleased to state:

(a) whether it is a fact that complaints have recently been received from the residents of Vasant Vihar Government Colony, New Delhi alleging wrong/fictitious electricity bills issued by the DESU;

(b) if so, what action Government have taken or propose to take against the officials responsible therefor;

(c) what steps are being taken to re-vamp the working of the DESU;